Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Condition:   Hemorrhagic Fever, Ebola Interventions:   Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo Sponsors:   Janssen Vaccines & Prevention B.V.;   Bavarian Nordic GmbH Recruiting - verified November 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials